AP39, A mitochondrially targeted hydrogen sulfide donor, exerts protective effects in renal epithelial cells subjected to oxidative stress in vitro and in acute renal injury in vivo

Shock

Volumn 45, Issue 1, 2016, Pages 88-97

  Ahmad, Akbar ^a   Olah, Gabor ^a   Szczesny, Bartosz ^a,b   Wood, Mark E ^c   Whiteman, Matthew ^d   Szabo, Csaba ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b SHRINERS HOSPITALS FOR CHILDREN   (United States)

^c UNIVERSITY OF EXETER   (United Kingdom)

^d UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

Author keywords

H2S donor; ischemia; mitochondria; oxidative stress; renal injury

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATININE; DICHLOROFLUORESCEIN; GLUCOSE OXIDASE; HYDROGEN PEROXIDE; HYDROGEN SULFIDE; INTERLEUKIN 12; LACTATE DEHYDROGENASE; MALONALDEHYDE; MYELOPEROXIDASE; UNCLASSIFIED DRUG; [10 OXO 10 [4 (3 THIOXO 3H 1,2 DITHIOL 5YL)PHENOXY]DECYL]TRIPHENYL PHOSPHONIUM BROMIDE; AP39 COMPOUND; ORGANOPHOSPHORUS COMPOUND; THIOKETONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CULTURE MEDIUM; DNA DAMAGE; IN VITRO STUDY; KIDNEY EPITHELIUM; KIDNEY INJURY; KIDNEY ISCHEMIA; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXIDATIVE STRESS; RAT; RENAL PROTECTION; REPERFUSION INJURY; TUNEL ASSAY; UREA NITROGEN BLOOD LEVEL; ACUTE KIDNEY INJURY; ANIMAL; CELL CULTURE; CELL HYPOXIA; CELL PROTECTION; DOSE RESPONSE; DRUG EFFECTS; EPITHELIUM CELL; METABOLISM; MITOCHONDRION; PHYSIOLOGY; PRECLINICAL STUDY; PROCEDURES; SPRAGUE DAWLEY RAT;

ACUTE KIDNEY INJURY; ANIMALS; CELL HYPOXIA; CELLS, CULTURED; CYTOPROTECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; EPITHELIAL CELLS; HYDROGEN SULFIDE; MALE; MITOCHONDRIA; ORGANOPHOSPHORUS COMPOUNDS; OXIDATIVE STRESS; RATS, SPRAGUE-DAWLEY; THIONES;

EID: 84952330354     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000478     Document Type: Article

References (35)

1. Paller MS: The cell biology of reperfusion injury in the kidney. J Invest Med 42:632-639, 1994.
2. Kribben A, Edelstein CL, Schrier RW: Pathophysiology of acute renal failure. J Nephrol 12:s142-s151, 1999.
3. Szabo C: Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 6:917-935, 2007.
4. Wallace JL, Wang R: Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter. Nat Rev Drug Discov 14:329-345, 2015.
5. Szabo C: Medicinal chemistry and therapeutic applications of the gasotransmitters nitric oxide, carbon monoxide and hydrogen sulfide. Burgers Medicinal Chem 5:265-367, 2010.
6. Martelli A, Testai L, Breschi MC, Blandizzi C, Virdis A, Taddei S, Calderone V: Hydrogen sulphide: novel opportunity for drug discovery. Med Res Rev 32:1093-1130, 2012.
7. Trionnaire SL, Perry A, Szczesny B, Szabo C, Winyard PG, Whatmore JL, Wood ME, Whiteman M: The synthesis and functional evaluation of a mitochondria-Targeted hydrogen sulfide donor, (10-oxo-10-(4-(3-Thioxo-3H-1, 2-dithiol-5-yl)nphenoxy) decyl)triphenylphosphonium bromide (AP39). Med Chem Commun 5:728-736, 2014.
8. Szczesny B, Módis K, Yanagi K, Coletta C, Le Trionnaire S, Perry A, Wood ME, Whiteman M, Szabo C: AP39, a novel mitochondria-Targeted hydrogen sulfide donor, stimulates cellular bioenergetics, exerts cytoprotective effects and protects against the loss of mitochondrial DNA integrity in oxidatively stressed endothelial cells in vitro. Nitric Oxide 41:120-130, 2014.
9. Szabo C, Ransy C, Módis K, Andriamihaja M, Murghes B, Coletta C, Olah G, Yanagi K, Bouillaud F: Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part I. Biochemical and physiological mechanisms. Br J Pharmacol 171:2099-2122, 2014.
10. Versteilen AM, Di Maggio F, Leemreis JR, Groeneveld AB, Musters RJ, Sipkema P: Molecular mechanisms of acute renal failure following ischemia/reperfusion. Int J Artif Organs 27:1019-1029, 2004.
11. Tirapelli LF, Bagnato VS, Tirapelli DP, Kurachi C, Barione DF, Tucci S Jr, Suaid HJ, Cologna AJ, Martins AC: Renal ischemia in rats: mitochondria function and laser autofluorescence. Transplant Proc 40:1679-1684, 2008.
12. Hall AM, Rhodes GJ, Sandoval RM, Corridon PR, Molitoris BA: In vivo multiphoton imaging of mitochondrial structure and function during acute kidney injury. Kidney Int 83:72-83, 2013.
13. Szoleczky P, Módis K, Nagy N, Dóri Tóth Z, DeWitt D, Szabó C, Gero D: Identification of agents that reduce renal hypoxia-reoxygenation injury using cell-based screening: purine nucleosides are alternative energy sources in LLC-PK1 cells during hypoxia. Arch Biochem Biophys 517: 53-70, 2012.
14. Brunyanszki A, Olah G, Coletta C, Szczesny B, Szabo C: Regulation of mitochondrial poly (ADP-Ribose) polymerase activation by the b-Adrenocep tor/cAMP/protein kinase A axis during oxidative stress. Mol Pharmacol 86:450-462, 2014.
15. Di Paola R, Genovese T, Impellizzeri D, Ahmad A, Cuzzocrea S, Esposito E: The renal injury and inflammation caused by ischemia-reperfusion are reduced by genetic inhibition of TNF-AR1: A comparison with infliximab treatment. Eur J Pharmacol 700:134-146, 2013.
16. Coletta C, Módis K, Oláh G, Brunyánszki A, Herzig DS, Sherwood ER, Ungvári Z, Szabo C: Endothelial dysfunction is a potential contributor to multiple organ failure and mortality in aged mice subjected to septic shock: preclinical studies in a murine model of cecal ligation and puncture. Crit Care 18:511, 2014.
17. Soriano FG, Lorigados CB, Pacher P, Szabó C: Effects of a potent peroxynitrite decomposition catalyst in murine models of endotoxemia and sepsis. Shock 35:560-566, 2011.
18. Nicholls P, Marshall DC, Cooper CE, Wilson MT: Sulfide inhibition of and metabolism by cytochrome c oxidase. Biochem Soc Trans 41:1312-1316, 2013.
19. Goubern M, Andriamihaja M, Nübel T, Blachier F, Bouillaud F: Sulfide, the first inorganic substrate for human cells. FASEB J 21:1699-1706, 2007.
20. Abou-Hamdan A, Guedouari-Bounihi H, Lenoir V, Andriamihaja M, Blachier F, Bouillaud F: Oxidation of H2S in mammalian cells and mitochondria. Methods Enzymol 554:201-228, 2015.
21. Módis K, Coletta C, Erdélyi K, Papapetropoulos A, Szabo C: Intramitochondrial hydrogen sulfide production by 3-mercaptopyruvate sulfurtransferase maintains mitochondrial electron flow and supports cellular bioenergetics. FASEB J 27:601-611, 2013.
22. Fu M, Zhang W, Wu L, Yang G, Li H, Wang R: Hydrogen sulfide (H2S) metabolism in mitochondria and its regulatory role in energy production. Proc Natl Acad Sci USA 109:2943-2948, 2012.
23. Szabo C, Coletta C, Chao C, Módis K, Szczesny B, Papapetropoulos A, Hellmich MR: Tumor-derived hydrogen sulfide, produced by cystathionineb-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer. Proc Natl Acad Sci USA 110:12474-12479, 2013.
24. Módis K, Panopoulos P, Coletta C, Papapetropoulos A, Szabo C: Hydrogen sulfide-mediated stimulation of mitochondrial electron transport involves inhibition of the mitochondrial phosphodiesterase 2A, elevation of cAMP and activation of protein kinase A. Biochem Pharmacol 86:1311-1319, 2013.
25. Módis K, Altaany Z, Untereiner A, Yang G, Wu L, Wang R, Szabo C: Hydrogen sulfide-induced S-sulfhydration of ATP synthase stimulates mitochondrial bioenergetics. Nitric Oxide 47:S53-S54, 2015.
26. Suzuki K, Olah G, Modis K, Coletta C, Kulp G, Gerö D, Szoleczky P, Chang T, Zhou Z, Wu L, Wang R, Papapetropoulos A, Szabo C: Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial function. Proc Natl Acad Sci USA 108:13829-13834, 2011.
27. Wen YD, Wang H, Kho SH, Rinkiko S, Sheng X, Shen HM, Zhu YZ: Hydrogen sulfide protects HUVECs against hydrogen peroxide induced mitochondrial dysfunction and oxidative stress. PLoS One 8:e53147, 2013.
28. Tomasova L, Pavlovicova M, Malekova L, Misak A, Kristek F, Grman M, Cacanyiova S, Tomasek M, Tomaskova Z, Perry A, Wood ME, Lacinova L, Ondrias K, Whiteman M: Effects of AP39, a novel triphenylphosphonium derivatised anethole dithiolethione hydrogen sulfide donor, on rat haemodynamic parameters and chloride and calcium Cav3 and RyR2 channels. Nitric Oxide 46:131-144, 2015.
29. Ikeda K, Marutani E, Hirai S, Wood ME, Whiteman M, Ichinose F: Mitochondria-Targeted hydrogen sulfide donor AP39 improves neurological outcomes after cardiac arrest in mice. Nitric Oxide 49:90-96, 2015.
30. Marques VP, Gonçalves GM, Feitoza CQ, Cenedeze MA, Fernandes Bertocchi AP, Damiao MJ, Pinheiro HS, Antunes Teixeira VP, dos Reis MA, Pacheco-Silva A, et al.: Influence of TH1/TH2 switched immune response on renal ischemia-reperfusion injury. Nephron Exp Nephrol 104:e48-e56, 2006.
31. Daemen MA, vant Veer C, Wolfs TG, Buurman WA: Ischemia/reperfusioninduced IFN-gamma up-regulation: involvement of IL-12 and IL-18. J Immunol 162:5506-5510, 1999.
32. Köken T, Serteser M, Kahraman A, Akbulut G, Dile ON: Which is more effective in the prevention of renal ischemia-reperfusion-induced oxidative injury in the early period in mice: interleukin (IL)-10 or anti-IL-12? Clin Biochem 37:50-55, 2004.
33. Tripatara P, Patel NS, Collino M, Gallicchio M, Kieswich J, Castigli S, Benetti E, Stewart KN, Brown PA, Yaqoob MM, Fantozzi R, Thiemermann C: Generation of endogenous hydrogen sulfide by cystathionine gamma-lyase limits renal ischemia/reperfusion injury and dysfunction. Lab Invest 88:1038-1048, 2008.
34. Simon F, Scheuerle A, Gröger M, Stahl B, Wachter U, Vogt J, Speit G, Hauser B, Mö ller P, Calzia E, Szabo C, Schelzig H, Georgieff M, Radermacher P, Wagner F: Effects of intravenous sulfide during porcine aortic occlusioninduced kidney ischemia/reperfusion injury. Shock 35:156-163, 2011.
35. Koning AM, Frenay AR, Leuvenink HG, van Goor H: Hydrogen sulfide in renal physiology, disease and transplantation-The smell of renal protection. Nitric Oxide 46:37-49, 2015.